RE- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria